BioSpace News Archive

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating Officer, a newly created position at the company.

Open-label study will evaluate the potential for DISC-0974, a first-in-class, anti-HJV (hemojuvelin) monoclonal antibody to improve anemia in myelofibrosis patients.

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that it has selected EVX-03 as the product candidate within its DNA technology platform to target a new indication with planned regulatory filing in H2 2022.

Data show that C3d-mediated tissue targeting of factor H results in potent, durable and efficacious local complement blockade without systemic complement inhibition.

Cullinan Oncology, Inc. (Cullinan Oncology) (Nasdaq: CGEM) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced the completion of its agreement with Taiho Pharmaceutical Co., Ltd. (Taiho) signed in May 2022.

BioVie Inc. (NASDAQ: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that a patent covering the use of terlipressin monotherapy to treat ascites patients who have not progressed to hepatorenal syndrome (“HRS”) has been issued by the U.S. Patent &Trademark Office.

Silo Enters into Commercial Evaluation License Agreement for Next Generation Liposomes.

Health Canada approved Enhertu™ (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within six months of completing neoadjuvant or adjuvant therapy.

Sid Taubenfeld with Extensive Experience in the Financial Markets and as a Biotech Executive Joins Tryp as Company Prepares to Expand Patient Access to Psilocybin-Based Treatments.

Matt Stang , CEO and Co-Founder of Delic Corp, will discuss the company’s strategic outlook for the remainder of the year and the latest developments at the nation’s largest ketamine provider, Ketamine Wellness Centers (KWC).